Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access

×

Login To Get Involved!


Forgot your username?


Forgot your password?

×

Join Us At EiR Now!

DNRS Roof Banner

 

DNRS Interactive DVD Series & Seminars

Ericksonian hypnosis in women with fibromyalgia syndrome

 

 

 

 

Rev Med Inst Mex Seguro Soc. 2007 Jul-Aug;45(4):395-401.

 

Ericksonian hypnosis in women with fibromyalgia syndrome.

 

Alvarez-Nemegyei J, Negreros-Castillo A, Nuño-Gutiérrez BL, Alvarez-Berzunza J, Alcocer-Martínez LM. Unidad de Investigació Médica, Hospital de Especialidades, Centro Médico Nacional "Ignacioi García Téllez," Mérida, Yucatan, Mexico. This email address is being protected from spambots. You need JavaScript enabled to view it. .

 

 

Background: fibromyalgia syndrome (FS) is a chronic, painful, generalized musculoskeletal disorder in which some efficacy for the conventional hypnosis modality has been claimed.

 

Objective: to assess the efficacy of the Ericksonian modality hypnosis in FS management.

 

Material and methods: forty-three FS female patients (44 +/- 4.7 years old) were included. They were randomized to receive for six months: Ericksonian hypnosis (EH; 20 subjects) or a sham-hypnosis (SH; 23 subjects). Every month, patient and physician global disease assessment, tender point count and the Fibromyalgia Impact Questionnaire (FIQ) were measured.

 

Results: during the follow-up, we did not find inter-group differences for the rate of change related to the baseline values for the patient and physician global disease assessment and the FIQ scores. At the third month (4.0 +/- 4.6 vs. 0.6 +/- 3.1; p = 0.02), and at the fourth month (5.0 +/- 4.6 vs. 0.8 +/- 4.0; p = 0.03) of follow-up, the participants who received EH had a significant reduction of the tender point count after adjustment for patient's age.

 

Conclusions: despite no effect was noted on the functional status and the patient and physician global assessment, EH produced a reduction in the number of tender points in FS. Thus, HE may be an adjuvant treatment for the management of FS patients.

 

PMID: 17949578 [PubMed - in process]

 

 

 

{mosgoogle}

 

{mos_sb_discuss:9}

 


 

 

Related Articles:

 

  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner